March 9, 2018

Orchard Therapeutics Scientific Founder Prof Donald Kohn Recognized with Pediatric Blood and Marrow Transplant Consortium Lifetime Achievement Award

London, UK  — Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that one of its scientific founders and scientific advisory board member, professor Donald Kohn, has been recognized with the Pediatric Blood and Marrow Transplant Consortium (PBMTC) Lifetime Achievement Award on Feb. 22, 2018 in Salt Lake City.

The PBMTC Lifetime Achievement Award recognizes outstanding individuals who have made major contributions to the field of pediatric hematopoietic stem cell transplantation. The award highlights and honors the contributions and careers of individuals whose work exemplifies the PBMTC mission statement: “To support research and education to improve the availability, safety, and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents.”

Professor Kohn has focused his career on the development of hematopoietic stem cell gene therapy for immunodeficiencies, hemoglobinopathies and inborn errors of metabolism. His work includes the development of tools for efficient gene addition or correction, and persistent transgene expression, for the amelioration of genetic disease.

Read More

Back to News